Multifunctional pH-sensitive polymeric nanoparticles for theranostics evaluated experimentally in cancer
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
A multifunctional pH-sensitive polymeric nanoparticle system was developed for simultaneous tumor magnetic resonance imaging (MRI) and therapy. The nanoparticles were self-assembled using the multi-block polymer poly(lactic acid)-poly(ethylene glycol)-poly(l-lysine)-diethylenetriamine pentaacetic acid (PLA-PEG-PLL-DTPA) and the pH-sensitive material poly(l-histidine)-poly(ethylene glycol)-biotin (PLH-PEG-biotin). The anti-hepatocellular carcinoma (HCC) drug sorafenib was encapsulated inside the nanoparticles. Gd ions were chelated to the DTPA groups which were distributed on the nanoparticle surface. Biotinylated vascular endothelial growth factor receptor (VEGFR) antibodies were linked to the surface biotin groups of nanoparticles through the avidin linker to form the target pH-sensitive theranostic nanoparticles (TPTN). TPTN exhibited spherical or ellipsoidal shapes, uniform particle size distribution (181.4 ± 3.4 nm), positive zeta potential (14.95 ± 0.60 mV), high encapsulation efficiency (95.02 ± 1.47%) and drug loading (2.38 ± 0.04%). The pH-sensitive sorafenib release from TPTN was observed under different pH values (47.81% at pH = 7.4 and 99.32% at pH = 5.0, respectively). In cell cytotoxicity studies, TPTN showed similar antitumor effect against HepG2 cells compared to solubilized sorafenib solution after pre-incubation in acid PBS (pH = 5.0) for 1 h in vitro (P > 0.05). In in vivo anti-tumor studies, TPTN showed significantly higher antitumor effect in H22 tumor (VEGFR overexpressed cell line) bearing mice compared to the solubilized sorafenib solution (oral or i.v. administration) group (P < 0.05). In the MRI test, the T1 relaxivity value of TPTN was 17.300 mM(-1) s(-1) which was 3.6 times higher than Magnevist® (r1 = 4.8 mM(-1) s(-1)). As a positive contrast agent, TPTN exhibited higher resolution and longer imaging time (more than 90 min) in the MRI diagnosis of tumor-bearing mice compared to Magnevist® (more than 60 min). Furthermore, histological examination of TBN (blank TPTN, without sorafenib loaded) showed no visible tissue toxicity compared to normal saline. Thus, TPTN possessed dual-loading drugs and imaging agents, active targeting and pH-triggered drug release properties in one platform with good biocompatibility. All of these results indicated that TPTN was a promising theranostic carrier which could be a platform for the development of novel multifunctional theranostic agents.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Thermo- and pH-responsive polymers in drug delivery☆
SCHMALJOHANN, D. (2006) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2006.09.020 · Cited by 3,023
Enhanced Permeability and Retention (EPR) Effect for Anticancer Nanomedicine Drug Targeting
Greish, K. (2010) · Methods in Molecular Biology · doi:10.1007/978-1-60761-609-2_3 · Cited by 841
Lee, E. S., Oh, K. T., Kim, D., Youn, Y. S., & Bae, Y. H. (2007) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.08.006 · Cited by 446
Liu, R., Li, D., He, B., Xu, X., Sheng, M., Lai, Y., Wang, G., & Gu, Z. (2011) · Journal of Controlled Release · doi:10.1016/j.jconrel.2011.02.031 · Cited by 157
Liu, D., Liu, F., Liu, Z., Wang, L., & Zhang, N. (2011) · Molecular Pharmaceutics · doi:10.1021/mp200402e · Cited by 108
Self-citation
Cited by
Mechanisms and biomaterials in pH-responsive tumour targeted drug delivery: A review
Kanamala, M., Wilson, W. R., Yang, M., Palmer, B. D., & Wu, Z. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.01.061 · Cited by 1,004
Polymeric Nanostructures for Imaging and Therapy
Elsabahy, M., Heo, G. S., Lim, S.-M., Sun, G., & Wooley, K. L. (2015) · Chemical Reviews · doi:10.1021/acs.chemrev.5b00135 · Cited by 508
A holistic approach to targeting disease with polymeric nanoparticles
Cheng, C. J., Tietjen, G. T., Saucier-Sawyer, J. K., & Saltzman, W. M. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4503 · Cited by 480
Ligand-installed nanocarriers toward precision therapy
Mi, P., Cabral, H., & Kataoka, K. (2020) · Advanced Materials · doi:10.1002/adma.201902604 · Cited by 350
pH-sensitive biomaterials for drug delivery
Zhuo, S., Zhang, F., Yu, J., Zhang, X., Yang, G., & Liu, X. (2020) · Molecules · doi:10.3390/molecules25235649 · Cited by 247
Siafaka, P., Üstündağ Okur, N., Karavas, E., & Bikiaris, D. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17091440 · Cited by 219
“They reported that the target pH-sensitive theranostic nanoparticles were produced after the chelation of the Gd ions to the DTPA groups, and the conjugation of biotinylated vascular endothelial growth factor receptor (VEGFR) antibodies was conjugated to the surface biotin groups of nanoparticles [287].”
BackgroundPolymeric nanoparticles—Promising carriers for cancer therapy
Xiao, X., Teng, F., Shi, C., Chen, J., Wu, S., Wang, B., Meng, X., Essiet Imeh, A., & Li, W. (2022) · Frontiers in Bioengineering and Biotechnology · doi:10.3389/fbioe.2022.1024143 · Cited by 176
“Polymeric nanocarriers with conjugated or encapsulated anticancer drugs, also known as polymeric nanomedicines, show a variety of different architectures including polymer–drug conjugates, micelles, nanospheres, nanogels, vesicles, and dendrimers (Alexis et al., 2010; Liu et al., 2014) (Figure 1).”
BackgroundLi, L., Wang, J., Kong, H., Zeng, Y., & Liu, G. (2018) · Science and Technology of Advanced Materials · doi:10.1080/14686996.2018.1528850 · Cited by 71
Aliphatic polyesters for medical imaging and theranostic applications
Nottelet, B., Darcos, V., & Coudane, J. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.06.023 · Cited by 68
Metadata
- Authors
- Liu, Y., Feng, L., Liu, T., Zhang, L., Yao, Y., Yu, D., Wang, L., & Zhang, N.
- Venue
- Nanoscale
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2014
- Volume
- 6
- Issue
- 6
- Pages
- 3231
- ISSN
- 2040-3364 (ISSN-L)
- 2040-3372
- OpenAlex
- W2110104127
- Cited by
- 126
- References
- 5
- FWCI
- 6.30
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.